R Fossati
Overview
Explore the profile of R Fossati including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
643
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Colombo N, Gadducci A, Sehouli J, Rulli E, Maenpaa J, Sessa C, et al.
Br J Cancer
. 2023 Feb;
128(8):1503-1513.
PMID: 36759720
Background: This trial investigated the hypothesis that the treatment with trabectedin/PLD (TP) to extend the platinum-free interval (TFIp) can improve overall survival (OS) in patients with recurrent ovarian cancer (OC)....
2.
Rosati G, Mosconi P, Torri V, Apolone G, Johnson F, Fossati R
Ann Oncol
. 2016 Feb;
27(6):1171.
PMID: 26912556
No abstract available.
3.
Rosati G, Ambrosini G, Barni S, Andreoni B, Corradini G, Luchena G, et al.
Ann Oncol
. 2015 Nov;
27(2):274-80.
PMID: 26578734
Background: Colorectal cancer is the third most common and the third most lethal cancer in both men and women in developed countries. About 75% of cases are first diagnosed when...
4.
Collinson F, Qian W, Fossati R, Lissoni A, Williams C, Parmar M, et al.
Ann Oncol
. 2014 Mar;
25(6):1165-71.
PMID: 24631948
Background: There is no clear consensus regarding systemic treatment of early-stage ovarian cancer (OC). Clinical trials are challenging because of the relatively low incidence and good prognosis. Initial results of...
5.
Dell Anna T, Signorelli M, Benedetti-Panici P, Maggioni A, Fossati R, Fruscio R, et al.
Br J Cancer
. 2012 Aug;
107(5):785-92.
PMID: 22864456
Background: The role of systematic aortic and pelvic lymphadenectomy (SAPL) at second-look surgery in early stage or optimally debulked advanced ovarian cancer is unclear and never addressed by randomised studies....
6.
Wagner U, Marth C, Largillier R, Kaern J, Brown C, Heywood M, et al.
Br J Cancer
. 2012 Jul;
107(4):588-91.
PMID: 22836511
Background: The CALYPSO phase III trial compared CD (carboplatin-pegylated liposomal doxorubicin (PLD)) with CP (carboplatin-paclitaxel) in patients with platinum-sensitive recurrent ovarian cancer (ROC). Overall survival (OS) data are now mature....
7.
Ganzinelli M, Mariani P, Cattaneo D, Fossati R, Fruscio R, Corso S, et al.
Eur J Cancer
. 2011 Jan;
47(7):1086-94.
PMID: 21216588
The purpose of this study was to investigate retrospectively the mRNA expression of genes involved in different DNA repair pathways implicated in processing platinum-induced damage in 171 chemotherapy-naïve ovarian tumours...
8.
Lissoni A, Colombo N, Pellegrino A, Parma G, Zola P, Katsaros D, et al.
Ann Oncol
. 2009 Feb;
20(4):660-5.
PMID: 19181826
Background: The efficacy and tolerability of the regimen containing paclitaxel and cisplatin (TP) in the neo-adjuvant treatment of locally advanced squamous cell cervical cancer are unknown. The TIP regimen (TP...
9.
Fruscio R, Colombo N, Lissoni A, Garbi A, Fossati R, Ieda N, et al.
Br J Cancer
. 2008 Feb;
98(4):720-7.
PMID: 18253120
To test the feasibility and efficacy of epirubicin and ifosfamide added to first-line chemotherapy with cisplatin and paclitaxel in a phase II randomised clinical trial. Patients with histologically proven epithelial...
10.
Marchini S, Marabese M, Marrazzo E, Mariani P, Cattaneo D, Fossati R, et al.
Ann Oncol
. 2007 Nov;
19(3):501-7.
PMID: 17998283
Background: P63 belongs to the 'p53 family' whose role in cancer progression has been recently revisited in light of the plethora of splicing variants that are generated. We analyzed the...